000650.SZ
Renhe Pharmacy Co., Ltd. [000650.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
000650.SZ Stock Summary
Top 10 Correlated Stocks
000650.SZ
In the News
000650.SZ Financial details
Company Rating
Buy
Market Cap
8.83B
Income
652.56M
Revenue
5.18B
Book val./share
4.01
Cash/share
1.91
Dividend
0.1
Dividend %
1.58%
Employees
7.06K
Optionable
No
Shortable
Yes
Earnings
29 Apr 2022
P/E
19.36
Forward P/E
-
PEG
54.04
P/S
2.3
P/B
1.57
P/C
3.3
P/FCF
66.8
Quick Ratio
3.22
Current Ratio
5.01
Debt / Equity
0.15
LT Debt / Equity
0
-
-
EPS (TTM)
0.47
EPS next Y
-
EPS next Q
-
EPS this Y
6.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
9.14%
Revenue last 5Y
5.13%
Revenue Q/Q
2.8%
EPS Q/Q
8.47%
-
-
-
-
SMA20
-2.74%
SMA50
1.11%
SMA100
7.77%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
8%
ROC
0.12%
Gross Margin
36%
Oper. Margin
20%
Profit Margin
12%
Payout
-
Shs Outstand
1.4B
Shs Float
977M
-
-
-
-
Target Price
-
52W Range
5.33-8.49
52W High
-21.13%
52W Low
+26.2%
RSI
42.25
Rel Volume
0.69
Avg Volume
37.11M
Volume
25.48M
Perf Week
-2.02%
Perf Month
-0.16%
Perf Quarter
14.1%
Perf Half Y
12.88%
-
-
-
-
Beta
0.353383
-
-
Volatility
0.07%, 0.12%
Prev Close
-0.63%
Price
6.31
Change
-0.47%
000650.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.13 | 3.56 | 3.66 | 3.25 | 3.56 | |
| Net income per share | 0.31 | 0.41 | 0.43 | 0.45 | 0.48 | |
| Operating cash flow per share | 0.41 | 0.46 | 0.55 | 0.69 | 0.56 | |
| Free cash flow per share | 0.37 | 0.4 | 0.44 | 0.52 | 0.2 | |
| Cash per share | 1.11 | 1.43 | 1.78 | 1.72 | 1.93 | |
| Book value per share | 2.45 | 2.75 | 3.04 | 4.01 | 3.82 | |
| Tangible book value per share | 1.95 | 2.33 | 2.87 | 3.83 | 3.37 | |
| Share holders equity per share | 2.45 | 2.75 | 3.04 | 4.01 | 3.82 | |
| Interest debt per share | 0 | 0 | 0 | 0.05 | 0.01 | |
| Market cap | 5.89B | 6.35B | 7.51B | 7.45B | 12.7B | |
| Enterprise value | 4.54B | 4.59B | 6.09B | 5.8B | 10.34B | |
| P/E ratio | 15.5 | 12.53 | 13.96 | 13.1 | 19.09 | |
| Price to sales ratio | 1.53 | 1.44 | 1.64 | 1.81 | 2.57 | |
| POCF ratio | 11.84 | 11.15 | 10.82 | 8.55 | 16.33 | |
| PFCF ratio | 12.97 | 12.71 | 13.66 | 11.41 | 45.68 | |
| P/B Ratio | 1.96 | 1.87 | 1.97 | 1.47 | 2.4 | |
| PTB ratio | 1.96 | 1.87 | 1.97 | 1.47 | 2.4 | |
| EV to sales | 1.18 | 1.04 | 1.33 | 1.41 | 2.1 | |
| Enterprise value over EBITDA | 7.6 | 5.96 | 7.26 | 6.88 | 10.48 | |
| EV to operating cash flow | 9.12 | 8.06 | 8.78 | 6.66 | 13.3 | |
| EV to free cash flow | 10 | 9.2 | 11.08 | 8.89 | 37.21 | |
| Earnings yield | 0.06 | 0.08 | 0.07 | 0.08 | 0.05 | |
| Free cash flow yield | 0.08 | 0.08 | 0.07 | 0.09 | 0.02 | |
| Debt to equity | 0.23 | 0.21 | 0.17 | 0.14 | 0.19 | |
| Debt to assets | 0.17 | 0.15 | 0.13 | 0.11 | 0.14 | |
| Net debt to EBITDA | -2.26 | -2.28 | -1.69 | -1.95 | -2.38 | |
| Current ratio | 3.49 | 4.2 | 5.33 | 5.6 | 4.19 | |
| Interest coverage | 1.17K | 1.44K | 16.18K | 553.45 | 1.06K | |
| Income quality | 1.31 | 1.12 | 1.29 | 1.53 | 1.17 | |
| Dividend Yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Payout ratio | 0.32 | 0.25 | 0.23 | 0.3 | 0.43 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.26 | 0.23 | 0.15 | 0.12 | 0.18 | |
| Capex to operating cash flow | -0.09 | -0.12 | -0.21 | -0.25 | -0.64 | |
| Capex to revenue | -0.01 | -0.02 | -0.03 | -0.05 | -0.1 | |
| Capex to depreciation | -0.5 | -0.76 | -1.5 | -2.6 | -5.77 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.14 | 5.03 | 5.43 | 6.38 | 6.42 | |
| ROIC | 0.35 | 0.66 | 0.31 | 0.22 | 0.4 | |
| Return on tangible assets | 0.12 | 0.14 | 0.13 | 0.1 | 0.12 | |
| Graham Net | 0.73 | 1.08 | 1.48 | 1.35 | 1.44 | |
| Working capital | 1.7B | 2.21B | 2.7B | 3.15B | 3.09B | |
| Tangible asset value | 2.39B | 2.88B | 3.58B | 4.84B | 4.67B | |
| Net current asset value | 1.69B | 2.2B | 2.69B | 3.14B | 3.07B | |
| Invested capital | 0 | 0 | 0 | 0.01 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 233.47M | 221.92M | 177.95M | 144.71M | 161.66M | |
| Average inventory | 456.45M | 494.47M | 528M | 487.33M | 526.53M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 35.79 | 31.07 | 19.64 | 21.88 | 20.99 | |
| Days of inventory on hand | 70.89 | 77.5 | 72.23 | 67.13 | 71.7 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 10.2 | 11.75 | 18.59 | 16.68 | 17.39 | |
| Inventory turnover | 5.15 | 4.71 | 5.05 | 5.44 | 5.09 | |
| ROE | 0.13 | 0.15 | 0.14 | 0.11 | 0.13 | |
| Capex per share | -0.04 | -0.06 | -0.12 | -0.17 | -0.36 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-06-30 | 2021-09-30 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.81 | 0.96 | 0.94 | 0.89 | 0.92 | |
| Net income per share | 0.13 | 0.14 | 0.11 | 0.1 | 0.11 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0.11 | 0 | -0.1 | 0.17 | 0.03 | |
| Cash per share | 1.15 | 1.54 | 1.89 | 1.96 | 1.91 | |
| Book value per share | 3.66 | 3.58 | 3.89 | 3.9 | 4.01 | |
| Tangible book value per share | 3.54 | 3.09 | 3.48 | 3.52 | 3.67 | |
| Share holders equity per share | 3.66 | 3.58 | 3.89 | 3.9 | 4.01 | |
| Interest debt per share | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Market cap | 15.03B | 11.46B | 10.81B | 8.93B | 7.8B | |
| Enterprise value | 14.04B | 10.14B | 9.53B | 7.39B | 7.14B | |
| P/E ratio | 21.04 | 14.61 | 17.35 | 15.48 | 12.46 | |
| Price to sales ratio | 13.19 | 8.57 | 8.24 | 7.15 | 6.07 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 94.74 | 2.27K | -77.23 | 37.71 | 220.85 | |
| P/B Ratio | 2.93 | 2.29 | 1.99 | 1.63 | 1.39 | |
| PTB ratio | 2.93 | 2.29 | 1.99 | 1.63 | 1.39 | |
| EV to sales | 12.32 | 7.58 | 7.27 | 5.91 | 5.56 | |
| Enterprise value over EBITDA | 60.31 | 37.53 | 43.58 | 36.93 | 32.25 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 88.48 | 2.01K | -68.12 | 31.18 | 202.32 | |
| Earnings yield | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | |
| Free cash flow yield | 0.01 | 0 | -0.01 | 0.03 | 0 | |
| Debt to equity | 0.14 | 0.23 | 0.17 | 0.16 | 0.15 | |
| Debt to assets | 0.11 | 0.17 | 0.13 | 0.12 | 0.12 | |
| Net debt to EBITDA | -4.27 | -4.91 | -5.83 | -7.73 | -2.95 | |
| Current ratio | 5.05 | 3.54 | 4.58 | 4.99 | 5.01 | |
| Interest coverage | 1.17K | 0 | 2.17K | 2.45K | 2.17K | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0.02 | 0 | 0 | 0 | 0 | |
| Payout ratio | 1.57 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | -0.03 | 0.11 | 0.06 | -0.02 | 0.13 | |
| Research and developement to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.12 | 0.19 | 0.18 | 0.18 | 0.17 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.02 | -0.07 | -0.03 | -0.03 | -0.06 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.24 | 3.36 | 3.12 | 3.01 | 3.18 | |
| ROIC | 0.05 | 0.06 | 0.05 | 0.05 | 0.03 | |
| Return on tangible assets | 0.03 | 0.04 | 0.03 | 0.02 | 0.03 | |
| Graham Net | 0.81 | 0.93 | 1.4 | 1.53 | 1.45 | |
| Working capital | 2.93B | 2.87B | 3.32B | 3.32B | 3.34B | |
| Tangible asset value | 4.96B | 4.32B | 4.87B | 4.94B | 5.13B | |
| Net current asset value | 2.93B | 2.86B | 3.29B | 3.3B | 3.32B | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 203.91M | 227.76M | 0 | 227.77M | 221.24M | |
| Average inventory | 446.32M | 530.52M | 0 | 518.6M | 464.18M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 27.25 | 26.12 | 24.82 | 25.84 | 22.93 | |
| Days of inventory on hand | 67.72 | 57.45 | 57.92 | 57.37 | 45.09 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 3.3 | 3.45 | 3.63 | 3.48 | 3.92 | |
| Inventory turnover | 1.33 | 1.57 | 1.55 | 1.57 | 2 | |
| ROE | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Capex per share | -0.02 | -0.07 | -0.03 | -0.03 | -0.06 |
000650.SZ Frequently Asked Questions
What is Renhe Pharmacy Co., Ltd. stock symbol ?
Renhe Pharmacy Co., Ltd. is a CN stock and trading under the symbol 000650.SZ
What is Renhe Pharmacy Co., Ltd. stock quote today ?
Renhe Pharmacy Co., Ltd. stock price is $6.31 today.
Is Renhe Pharmacy Co., Ltd. stock public?
Yes, Renhe Pharmacy Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 37.11M
- Market Capitalization 8.83B
- Employee 7.06K
- CEO Mr. Wei Zhang
- Headquarters Nanchang,CN
- IPO Date 1996-12-10
-
Website
https://www.renheyaoye.com 
Renhe Pharmacy Co., Ltd. produces and sells pharmaceutical products. It offers Chinese and western medicines and raw materials; and health-related products, including oral solid preparations and liquid preparations, large-volume and small-volume injections, topical lotions, liniments, suppositories, ointments, and other dosage forms of drugs and health-related products. The company was founded in 1996 and is headquartered in Nanchang, China.
